Court rejects investor probe request at Philips

On 10 October 2026 the Ondernemingskamer in Amsterdam declined requests to order a formal investigation into Koninklijke Philips N.V. The petition had been filed by the Vereniging Effectenbezitters, an investors’ association, together with a large group of investors. Their request related to the company’s handling of the widely reported 2021 sleep-apnea and ventilator matter. The decision means no court-ordered inquiry into Philips’ governance and communications will proceed in this case.

In its judgment, the commercial chamber reviewed an extensive file that included internal documents from Philips. After assessing this material, the court concluded that there were no grounded reasons to doubt the company’s policy or its course of events around the recall. This assessment was central to its rejection of the investors’ request for an inquiry.

The Ondernemingskamer found no basis to determine that Philips’ public statements about the 2021 sleep-apnea and ventilator issue had been too late, incorrect, or misleading. This conclusion addressed a core allegation from the investor group, which had sought scrutiny of the company’s communications. By stating that there were no grounded reasons to doubt Philips’ policy, the court effectively confirmed that it saw no sufficient indication of mismanagement in this area.

The ruling focused on the question of whether the legal threshold for initiating an investigation had been met. The court’s analysis of Philips’ policy and disclosures was confined to this procedural context. It did not convert those findings into broader determinations on operational performance or financial liability.

The decision clarifies that, in the court’s view, Philips’ governance and communications around the 2021 matter do not warrant an inquiry by the Ondernemingskamer. The judgment closes this specific attempt by the investor group to secure a court-ordered investigation. As a result, this legal avenue to probe the company’s internal decision-making and disclosure practices is now exhausted in this proceeding.

At the same time, the ruling is limited to the governance and communication questions placed before the chamber. It does not set out findings on possible operational failures by Philips’ former Respironics unit. It also does not address any liability questions regarding investor losses arising from the 2021 recall.

Philips stated that it welcomed the decision from the Ondernemingskamer. The company highlighted that the court had found no grounds to doubt a correct policy or proper conduct. In its response, Philips reiterated that it remains focused on patients and customers. It also emphasized continued execution of its plan, which includes ongoing remediation efforts connected to the 2021 sleep-apnea and ventilator matter.

The outcome provides clarity on one important strand of legal scrutiny facing Philips. With the request for a governance inquiry rejected, the company is signaling continuity in its approach to addressing the consequences of the recall. The emphasis on execution suggests an ongoing focus on remediation and stakeholder confidence within the boundaries set by the court’s ruling.